Canaccord lowered the firm’s price target on Clover Health (CLOV) to $3.20 from $3.70 and keeps a Buy rating on the shares. The firm said Clover took some lumps in 2025 alongside the rest of managed care with heightened medical costs, but the company closed out the year on a solid note without further deterioration. Heading into 2026, the company has strong tailwinds, namely being paid as a 4-star plan and favorable 2026 rates from CMS. In their view, the story is plausible and compelling.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLOV:
- Clover Health’s Counterpart Assistant associated with decrease in flu events
- Clover Health Highlights Transparency With Supplemental Earnings Q&A
- Clover Health becomes first player live on CMS Aligned Network
- Clover Health price target lowered to $2.75 from $3 at UBS
- Clover Health reports Q4 EPS (10c), consensus (5c)